The stock of Aptevo Therapeutics Inc (NASDAQ:APVO) hit a new 52-week low and has $1.59 target or 14.00% below today’s $1.85 share price. The 6 months bearish chart indicates high risk for the $35.56 million company. The 1-year low was reported on Nov, 2 by Barchart.com. If the $1.59 price target is reached, the company will be worth $4.98 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 140,543 shares traded hands. Aptevo Therapeutics Inc (NASDAQ:APVO) has risen 6.00% since October 3, 2016 and is uptrending. It has outperformed by 3.48% the S&P500.
According to Zacks Investment Research, “Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company’s platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.”
More notable recent Aptevo Therapeutics Inc (NASDAQ:APVO) news were published by: Businesswire.com which released: “Aptevo Therapeutics Completes Separation from Emergent BioSolutions” on August 01, 2016, also Quotes.Wsj.com with their article: “News Aptevo Therapeutics Inc.APVO” published on July 24, 2016, Seekingalpha.com published: “Aptevo Therapeutics: A Biotech Spinoff With Potential” on September 22, 2016. More interesting news about Aptevo Therapeutics Inc (NASDAQ:APVO) were released by: Globenewswire.com and their article: “Emergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 …” published on July 15, 2016 as well as Schaeffersresearch.com‘s news article titled: “Analyst Update: Aptevo Therapeutics Inc, PBF Energy Inc, and Cyberark Software Ltd” with publication date: September 09, 2016.
APVO Company Profile
Aptevo Therapeutics Inc. is a biotechnology company. The Firm focuses on oncology (cancer) and hematology (blood disease) therapeutics to manage patientsâ€™ lives. The Companyâ€™s segment is engaged in the discovery, development, commercialization and sale of sale oncology and hematology therapeutics. The Companyâ€™s core technology is the ADAPTIR (modular protein technology) platform. The Firm has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Companyâ€™s investigational-stage product candidates MOR209/ES414, ES210, ES425 and otlertuzumab are built on its ADAPTIR (modular protein technology) platform. The technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The mechanisms of action for MOR209/ES414, ES210, ES425 and otlertuzumab include redirected T-cell cytotoxicity (RTCC), by which a therapeutic molecule brings T-cells into contact with tumor cells and trigger tumor killing, or targeted delivery of cytokines (or immune modulating protein) to diseased cells. The structural differences of ADAPTIR molecules over monoclonal antibodies allow for the development of new ADAPTIR immunotherapeutics that engage disease targets in a manner and produce a signaling response. It provides product candidate generation, validation and pre-clinical and clinical development using the ADAPTIR platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.